Illumina (ILMN) Stock Forecast & Price Target

Q: What analysts cover Illumina?

Illumina has been rated by research analysts at Argus , Barclays , Canaccord Genuity Group , Citigroup , Deutsche Bank Aktiengesellschaft , Evercore , Guggenheim , JPMorgan Chase & Co. , Leerink Partners , Piper Sandler , Royal Bank Of Canada , Sanford C. Bernstein , Stifel Nicolaus , TD Cowen , UBS Group , Weiss Ratings , and Zacks Research in the past 90 days.

$255.38 +7.92 (+3.20%)

Closing price 04:00 PM Eastern

Extended Trading

$258.50 +3.12 (+1.22%)

As of 05:56 PM Eastern

Compare

Illumina - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 18 Analyst Ratings

Sell
2

Hold
6

Buy
10

Based on 18 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 2 have given a sell rating, 6 have given a hold rating, and 10 have given a buy rating for ILMN.

Consensus Price Target

$199.13
-22.03% Downside

According to the 18 analysts' twelve-month price targets for Illumina, the average price target is $199.13. The highest price target for ILMN is $260.00, while the lowest price target for ILMN is $113.00. The average price target represents a forecasted downside of -22.03% from the current price of $255.38.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ILMN Analyst Ratings Over Time

Type	Current Forecast 9/23/25 to 9/23/26	1 Month Ago 8/24/25 to 8/24/26	3 Months Ago 6/25/25 to 6/25/26	1 Year Ago 9/23/24 to 9/23/25
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$199.13	$188.40	$143.56	$119.71
Forecasted Upside	-22.03% Downside	-15.60% Downside	-19.19% Downside	20.46% Upside
Consensus Rating	Hold	Hold	Hold	Hold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Illumina Stock vs. The Competition

Type	Illumina	Healthcare Companies	Broader Market
Consensus Rating Score	2.44	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	-19.53% Downside	708.19% Upside	17.93% Upside
News Sentiment Rating	Positive News See Recent ILMN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/9/2026	UBS Group 4 of 5 stars	Doug Schenkel Not Rated	Upgrade	Neutral ➝ Buy	$135.00 ➝ $260.00	+23.19%
9/3/2026	Argus 3 of 5 stars	Jasper Hellweg Not Rated	Boost Target	Buy	$180.00 ➝ $235.00	+9.48%
9/1/2026	Zacks Research 4 of 5 stars		Downgrade	Strong-Buy ➝ Hold
8/31/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
8/5/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold
8/3/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kyle Mikson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$190.00 ➝ $205.00	0.00%
8/3/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sell	$95.00 ➝ $113.00	-44.90%
8/3/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Westenberg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$200.00 ➝ $225.00	+11.29%
7/31/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$170.00 ➝ $230.00	+15.48%
7/31/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eve Burstein Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform	$215.00	+4.83%
Get the Latest News and Ratings for ILMN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.
7/31/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Subbu Nambi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$200.00 ➝ $226.00	+10.20%
7/31/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Underweight	$145.00 ➝ $160.00	-21.99%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$220.00 ➝ $230.00	+14.36%
7/31/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Brennan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$192.00 ➝ $210.00	+5.17%
7/31/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Arias Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$155.00 ➝ $225.00	+13.72%
7/17/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Puneet Souda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$175.00 ➝ $210.00	+13.91%
7/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
5/14/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$155.00	+6.90%
2/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Catherine Ramsey Schulte Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$137.00	+13.26%
8/4/2025	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target	Overweight	$110.00	+12.52%
8/4/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tejas Savant Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$100.00 ➝ $105.00	+8.45%
7/11/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sung Ji Nam Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$125.00	+24.94%
2/28/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	S. Gupta Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$100.00	+18.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:04 PM ET.

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 22, 2026. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

Here are some ways that investors could benefit from investing in Illumina, Inc.:

Illumina, Inc. recently reported strong financial performance for the quarter ended July 30, 2026, beating analyst expectations with an earnings per share of $1.31 compared to the consensus estimate of $1.23, while also generating revenue of $1.16 billion, which exceeded the projected $1.13 billion and represented a 9.4% year-over-year increase.
The company has demonstrated significant momentum, with the stock price reaching a 52-week high of $250.06 and currently trading at $238.82, reflecting a substantial appreciation from its 52-week low of $88.00 and indicating strong investor confidence in its genomic analysis technologies.
Illumina, Inc. has received positive revisions from major financial institutions, with Stifel Nicolaus raising its price target to $225.00 and JPMorgan Chase & Co. increasing its target to $230.00, both maintaining buy or overweight ratings, which suggests institutional support for the company's growth trajectory.
The company maintains a healthy financial position with a current ratio of 1.80 and a quick ratio of 1.40, indicating sufficient liquidity to cover short-term obligations, while its debt-to-equity ratio of 0.53 suggests a moderate level of leverage that supports its operational stability.
Illumina, Inc. continues to expand its market presence through its Core Illumina and GRAIL segments, offering advanced sequencing instruments like the NovaSeq and NextSeq platforms, which are critical for researchers and healthcare providers in analyzing genetic variation and biological functions.

Illumina
Bear Case

Investors should be bearish about investing in Illumina, Inc. for these reasons:

The current stock price of $238.82 is significantly above the consensus price target of $199.12, suggesting that the stock may be overvalued relative to analyst expectations, which could lead to potential downside if the market corrects to align with these targets.
Insider selling has been notable, with Director Keith Meister selling a total of 119,501 shares on September 4, 2026, and other insiders selling over 2 million shares valued at approximately $436.6 million in the last ninety days, which may signal a lack of confidence from those with the most knowledge of the company's internal operations.
Illumina, Inc. carries a high beta of 1.46, indicating that its stock is more volatile than the overall market, which could result in larger price swings and higher risk for investors, especially during periods of market uncertainty or economic downturns.
The company's price-to-earnings ratio of 44.56 is relatively high, suggesting that investors are paying a premium for each dollar of earnings, which may limit the stock's upside potential if earnings growth does not accelerate to justify this valuation multiple.
Short interest has increased slightly, with 9,720,715 shares shorted as of August 31, 2026, representing a 2.7% month-over-month increase, which could indicate that some market participants are betting against the stock's future performance, potentially leading to downward pressure on the price.

ILMN Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $199.13, with a high forecast of $260.00 and a low forecast of $113.00.

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.

According to analysts, Illumina's stock has a predicted downside of -22.03% based on their 12-month stock forecasts.

Over the previous 90 days, Illumina's stock had 3 upgrades and 2 downgrades by analysts.

Illumina has been rated by research analysts at Argus, Barclays, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Piper Sandler, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, UBS Group, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Illumina more than other "healthcare" companies. The consensus rating score for Illumina is 2.44 while the average consensus rating score for "healthcare" companies is 2.31. Learn more on how ILMN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Illumina Recommendations

MarketBeat monitors more than a dozen sources for Illumina analyst ratings, with the most recent rating issued on 9/9/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Illumina (ILMN) Stock Forecast & Price Target